Cross-country migration linked to people who inject drugs challenges the long-term impact of national HCV elimination programmes
Vrancken, B. ; Cuypers, L. ; Pérez, A.B. ; Chueca, N. ; Anton-Basantas, J. ; de la Iglesia, A. ; Fuentes, J. (Universidad de Zaragoza) ; Pineda, J.A. ; Téllez, F. ; Bernal, E. ; Rincón, P. ; Von Wichman, M.A. ; Fuentes, A. ; Vera, F. ; Rivero-Juárez, A. ; Jiménez, M. ; Vandamme, A.M. ; García, F.
Resumen: To the Editor:
As of 2018, the majority of Western European countries – including Spain – have lifted restrictions to therapy based on disease severity in the context of HCV infections.1 Long overdue, most national elimination programmes now also include access to care for people who inject drugs (PWID), 2 who are at the core of ongoing HCV transmission.3 Macías et al.4 have recently shown in this Journal that high viral cure rates can be achieved in this group, hereby providing evidence that targeting PWID in treatment programmes is worthwhile. However, the extent to which such national efforts can reduce the HCV burden not only depends on the uptake into care and treatment success rates, it is also determined by the relative importance of within-country transmission and virus importation from elsewhere.
As the chronic nature of most HCV infections hampers reliably reconstructing contact networks from patient interviews, virus genetic data can be a valuable alternative source of information for elucidating the geographic history of virus lineages (e.g. [5], [6]). Using such data, we have recently shown that for the most prevalent subtype among PWID in Spain (40%, 7), HCV1a, infections often link to infections abroad – in recent years >50% link to Western European countries, mostly European Union (EU) member states – as opposed to other infections ...
Idioma: Inglés
DOI: 10.1016/j.jhep.2019.08.010
Año: 2019
Publicado en: JOURNAL OF HEPATOLOGY 71, 6 (2019), 1270-1272
ISSN: 0168-8278
Factor impacto JCR: 20.582 (2019)
Categ. JCR: GASTROENTEROLOGY & HEPATOLOGY rank: 2 / 88 = 0.023 (2019) - Q1 - T1
Factor impacto SCIMAGO: 6.817 - Hepatology (Q1)
Financiación: info:eu-repo/grantAgreement/ES/FEDER/RD16-0025-0040
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI15-00713
Tipo y forma: (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2021-02-24-12:54:45)
Visitas y descargas
As of 2018, the majority of Western European countries – including Spain – have lifted restrictions to therapy based on disease severity in the context of HCV infections.1 Long overdue, most national elimination programmes now also include access to care for people who inject drugs (PWID), 2 who are at the core of ongoing HCV transmission.3 Macías et al.4 have recently shown in this Journal that high viral cure rates can be achieved in this group, hereby providing evidence that targeting PWID in treatment programmes is worthwhile. However, the extent to which such national efforts can reduce the HCV burden not only depends on the uptake into care and treatment success rates, it is also determined by the relative importance of within-country transmission and virus importation from elsewhere.
As the chronic nature of most HCV infections hampers reliably reconstructing contact networks from patient interviews, virus genetic data can be a valuable alternative source of information for elucidating the geographic history of virus lineages (e.g. [5], [6]). Using such data, we have recently shown that for the most prevalent subtype among PWID in Spain (40%, 7), HCV1a, infections often link to infections abroad – in recent years >50% link to Western European countries, mostly European Union (EU) member states – as opposed to other infections ...
Idioma: Inglés
DOI: 10.1016/j.jhep.2019.08.010
Año: 2019
Publicado en: JOURNAL OF HEPATOLOGY 71, 6 (2019), 1270-1272
ISSN: 0168-8278
Factor impacto JCR: 20.582 (2019)
Categ. JCR: GASTROENTEROLOGY & HEPATOLOGY rank: 2 / 88 = 0.023 (2019) - Q1 - T1
Factor impacto SCIMAGO: 6.817 - Hepatology (Q1)
Financiación: info:eu-repo/grantAgreement/ES/FEDER/RD16-0025-0040
Financiación: info:eu-repo/grantAgreement/ES/ISCIII/PI15-00713
Tipo y forma: (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2021-02-24-12:54:45)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2021-02-24, last modified 2021-02-24